Incyte Corporation: Why Jakafi Is No Longer The Real Story Here (NASDAQ:INCY)
· seekingalpha.com
Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.
When it comes to Incyte Corporation ( INCY ), the latest financials would ultimately re-rate them from a Jakafi-centric cash-generating pharma story with some i...